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Early Inflammatory Changes in the ‘‘Perilesional
Skin’’ of Psoriatic Plaques: Is there Interaction
between Dendritic Cells and Keratinocytes?
Mayumi Komine1, Masaru Karakawa1, Tomonori Takekoshi1, Naoki Sakurai1, Yosaku Minatani1,
Hiroshi Mitsui1, Yayoi Tada1, Hidehisa Saeki1, Akihiko Asahina1 and Kunihiko Tamaki1
Early inflammatory changes in psoriatic plaques were investigated immunohistochemically by studying the
normal-appearing skin adjacent to the plaques (perilesional skin), lesional skin, and distant uninvolved skin
from psoriasis patients. Perilesional epidermis contained numerous CD1a-positive Langerhans cells, some of
which expressed HLA-DR, CD83, CD80, and CD86, at the same time expressing Langerin. There were also
numerous CD83-positive, CD11c-positive, Langerin-negative dendritic cells (DCs) in the epidermal–dermal
junction of perilesional skin. CD3-positive T lymphocytes were sparse in the perilesional skin. Perilesional
epidermis expressed keratin K6 and K16, inflammatory keratins, and C/EBPb, a transcription factor related to
inflammatory cytokines. Our results demonstrated the abundant distribution of activated DCs in the
perilesional skin of psoriatic plaques, where early inflammatory changes occur in the epidermal keratinocytes,
which suggests their involvement in the provocation of epidermal inflammation in the perilesional epidermis
and further pathogenic roles in the formation of psoriatic plaques.
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INTRODUCTION
Psoriasis is a well-established entity and investigations have
characterized its pathophysiological abnormalities, but its
etiology is unknown. Recent observations, such as successful
treatment with cytotoxic T-lymphocyte-associated antigen 4-
immunoglobulin (Abrams et al., 1999), support the hypothesis
that antigen-presenting dendritic cells (DCs) have critical roles
in the pathogenesis of psoriasis. Recent reviews on psoriasis
have made many suggestions for the pathogenic involvement
of DCs. (Chamian and Krueger, 2004; Bos et al., 2005;
Bowcock and Krueger, 2005). Langerhans cells (LCs) are the
antigen-presenting DCs in the epidermis, whose pathogenic
role in psoriasis is not yet elucidated, however, their existence
is thought essential to the progression of the disease.
Psoriatic plaques usually start as small papules enlarging
outward to form well-demarcated typical lesions. The
peripheral lesion of psoriatic plaques is thought to be more
active than the center of the plaque. There have been several
reports investigating the early event occurring in the
peripheral lesion of psoriatic plaques and the normal looking
marginal lesion surrounding the psoriatic plaques (De Mare
et al., 1990; Van de Kerkhof et al., 1991; Castelijns et al.,
1999; Mommers et al., 2000). We have investigated the clues
to early events at the periphery and in the normal-appearing
skin surrounding the psoriatic plaques (perilesional skin) to
seek the subclinical phenomena preceding the formation of
the psoriatic skin lesion, especially in DCs infiltrating the skin
in marginal, perilesional areas of psoriatic plaques.
RESULTS
The density and the number of CD1a-positive cells are
increased in the epidermis of normal-appearing skin adjacent to
the plaque (perilesional skin) compared to the epidermis of the
skin inside the plaque (lesional skin) or normal-appearing skin
(uninvolved skin or distant area skin)
To assess the density and the number of CD1a-positive cells,
we utilized the image analysis software Image-pro plus
(Planetron, Tokyo, Japan) to quantify the area of CD1a-
positive staining.
The area of CD1a-positive staining was selected by
choosing a brown color positive for CD1a and the ratio of
the positive area to the entire epidermal area was calculated.
The same procedure was applied for at least two different
sights from each area of the sections and for all the biopsy
specimens from the patients. The results were summarized
and statistical evaluations were made. The number of CD1a-
positive cells was counted along a 2-mm length of each area
in all sections (per low power field) (Figure 2).
The positive area inside the plaque (lesion) was sparsely
distributed in the thickened psoriasiform epidermis (Figure
2a), whereas the positive area in the epidermis of perilesional
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skin was condensed including a strong-positive reaction in
the intercellular space of keratinocytes (KC) (Figure 2b). The
normal-appearing skin close to perilesional skin (uninvolved)
showed positive staining in the intercellular space of KCs
together with less intracellular staining of putative LCs (Figure
2c). The normal-appearing skin distant from the lesion
(distant area skin) showed much less intercellular staining
compared to perilesional skin (Figure 2d). The results of
quantification are shown in Figure 2e.
The number of CD1a-positive LCs per 2 mm of epidermis
(per low power field) was highest in the perilesional area of
psoriatic plaque and modestly increased inside the plaque
(lesion) compared to uninvolved or distant area skin (Figure 2f).
CD3-positive cells were abundant inside the plaque (lesional),
whereas they were few in the perilesional area, uninvolved, and
distant skin
A dense infiltration of CD3-positive T lymphocytes was seen
inside the lesion of psoriatic plaques (Figure 3a), whereas
only sparse positive staining was seen outside the lesion even
in the perilesional area (Figure 3b) where a lot of CD1a-
positive cells were observed. The ratio of the positive staining
area to the area including the entire epidermis and the
papillary dermis was calculated and is shown in Figure 3e.
Characterization of infiltrating DCs with a series of activated
markers
To characterize the nature of DCs in lesional and perilesional
skin of psoriatic plaques, we stained the same samples with
antibodies against several markers of DCs.
HLA-DR is one of the major histocompatibility complex
class II chains, expressed on activated KCs and mononuclear
cells (Griffiths et al., 1989). HLA-DR expression is enhanced
when DCs are activated and become mature, which serves
for antigen presentation (Lutz and Schuler, 2002). There was
an extensive infiltration of HLA-DR-positive cells in the
lesional skin of psoriatic plaques including the positive
staining on LCs, especially surrounding the papillary dermis
(Figure 4a). Some of the LCs in the perilesional epidermis also
expressed HLA-DR (Figure 4b), whereas there were only a
few HLA-DR-positive LCs within uninvolved area close to
perilesional skin or distant area skin from the lesion (data not
shown), which suggests that LCs in the perilesional epidermis
expressed enhanced levels of HLA-DR.
Uninvolved
Peri-lesional
Lesional
Distant area
Figure 1. A scheme of biopsies illustrating lesional, perilesional, uninvolved,
and distant area skin taken from psoriatic patients.
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Figure 2. Cryosections of skin samples from psoriatic patients were
immunohistochemically stained with anti-CD1a antibody. (a) CD1a-positive
cells in the lesional epidermis of a psoriatic patient. (b) CD1a-positive cells in
the perilesional epidermis. (c) CD1a-positive cells in uninvolved skin from a
psoriatic patient. (d) CD1a-positive cells in distant are skin.
(a–d) Bar¼ 200mm. (e) The area positively stained with anti-CD1a antibody
was selected and the ratio of positive area to the whole epidermis was
calculated with the image analysis software Image Pro Plus from Planetron
(Tokyo, Japan). Perilesional epidermis had a significantly higher ratio of
CD1a-positive area to the lesional epidermis and distant area skin. (f) The
number of CD1a-positive cells in the unit length of epidermis (per low power
field) was counted. Perilesional epidermis contained significantly more
CD1a-positive cells than uninvolved and distant area skin epidermis.
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CD80 and CD86, the costimulatory molecules expressed
on activated LCs (Lutz and Schuler, 2002) were also stained.
Considerable numbers of LCs in the lesional and perilesional
epidermis were positive for CD80 (Figure 4c and d) and CD86
(Figure 4 e and f), suggesting that some of the LCs in the
lesional and perilesional epidermis express the costimulatory
molecules required for antigen presentation (Figure 4 c–f).
CD11c is also one of the markers of DCs. It has recently
been shown that CD11c-positive DCs abundantly distribute
in the lesional skin of patients with psoriasis (Lowes et al.,
2005). There were many CD11c-positive cells in the dermis
and epidermis of psoriatic lesions (Figure 4g) and there were
fewer, but a constant number of CD11c-positive cells in
perilesional epidermis as well as along the epidermal–dermal
junction (Figure 4h).
BDCA2 is a marker for plasmacytoid DCs, the existence of
which has been recently shown in psoriasis (Nestle et al.,
2005). BDCA2 was detected only in a few cells of lesional
mid dermis and a few cells in the lesional papillary dermis
(Figure 4i and j). The majority of the perilesional DCs were
negative for BDCA2.
CD83, one of the maturation markers for DCs (Bowcock
and Krueger, 2005), was also detected in the epidermal LCs
in the perilesional epidermis. In addition to that population,
there were numerous CD83-positive DCs along the epider-
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Figure 3. Cryosections of skin samples from psoriatic patients were
immunohistochemically stained with anti-CD3 antibody. (a) CD3-positive
cells were densely distributed in the lesional skin of psoriatic patients.
(b) Perilesional, (c) uninvolved, and (d) distant area skin contained much
less CD3-positive cells compared with lesional skin. (a–d) Bar¼ 200mm.
(e) The ratio of CD3-positive area to the unit area of epidermis and papillary
dermis was calculated with image analysis software. Lesional epidermis has
a significantly higher ratio of CD3-positive area to the perilesional and
uninvolved skin epidermis.
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Figure 4. Immunohistochemistry of lesional and peri-lesional skin of psoriasis patients with antibodies of various DC markers. (a) HLA-DR-positive cells
in the lesional skin of a psoriatic patient. (b) HLA-DR-positive cells in the perilesional skin of a psoriatic patient. There are HLA-DR-positive DCs in the
perilesional epidermis. (c) CD80-positive cells in the epidermis of lesional skin of a psoriatic patient. (d) CD80-positive cells in the perilesional skin of
a psoriatic patient. (e) CD86-positive cells in the epidermis of lesional skin of a psoriatic patient. (f) CD86-positive cells in the epidermis of perilesional
skin of a psoriatic patient. (g) CD11c-positive cells in the lesional skin. (h) CD11c-positive cells in the perilesional skin. There were HLA-DR-positive,
CD86-positive, CD80-positive, and CD11c-positive DCs in the perilesional epidermis. (i) There were only a few BDCA2-positive cells in the mid dermis
of psoriatic lesions. (j) Only a small number of BDCA2-positive cells were seen in the papillary dermis of psoriatic lesions. (a–j) Bar¼ 100 mm.
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mal–dermal junction in the lesional (Figure 5a) and perile-
sional skin (Figure 5b). The numbers of CD83-positive DCs
along the epidermal–dermal junction in lesional, perilesional,
uninvolved, and distant area skin were counted and are
shown in Figure 5c. These CD83-positive DCs were CD11c-
positive, CD11b-negative (data not shown), CD1a-negative,
and Langerin-negative. Some of these results were confirmed
by the double-immunofluorescent technique and the result of
double staining with anti-Langerin and anti-CD83 antibody in
perilesional skin is shown in Figure 5d. As shown in Figure
5d, epidermal LCs were positive for CD83 as well as Langerin
and there were CD83-positive Langerin-negative DCs along
the dermal–epidermal junction.
Markers for activated KCs were detected in the epidermis of
perilesional and uninvolved skin
Keratin 6, 16, and 17 are keratins expressed in activated KCs
especially during inflammation. Keratin 16 is often utilized as
a marker for inflammation in the epidemis and has been
reported to be positive in the perilesional epidermis of
psoriatic plaques (Castelijns et al., 1999). Keratin 6 and 16
make heteropolymers to form keratin filaments in the
inflamed epidermis and are usually expressed in pairs.
Keratin K6 and K16 was detected in the adjacent, perile-
sional, slightly acanthotic epidermis of psoriatic plaques
(Figure 6a and b), which is consistent with previous reports.
C/EBPb is a transcription factor, which can induce the
expression of various inflammatory cytokines and other
molecules including interleukin (IL)-6 (Kinoshita et al.,
1992) and keratin K6 (Komine et al., 2000). C/EBPb is
expressed in the nucleus only in the granular layer of normal
epidermis (Maytin and Habener, 1998). Our result demon-
strated strong nuclear staining throughout the epidermis of
psoriatic lesions and in the adjacent perilesional skin of
psoriatic plaques, whereas it was detected only in the granular
layer of the epidermis from normal healthy controls or distant
uninvolved skin of psoriasis patients (Figure 6c and d).
DISCUSSION
CD1aþCD11cþ LangerinþDCs (LCs) were increased in
number in the lesional skin compared with normal appearing
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Figure 5. Immunohistochemistry with anti-CD83 antibody. The number of
CD83-positive cells per high power field was counted and statistically
analyzed. (a) CD83-positive cells in the lesional skin. (b) CD83-positive cells
in the perilesional skin. (a and b) Bar¼ 100mm. (c) The number of CD83-
positive cells in the epidermal–dermal junction of perilesional skin is
significantly higher than that of distant area skin. (d) Double staining with
anti-CD83 antibody and anti-Langerin antibody. Merged image shows that
there are CD83-positive, Langerin-positive epidermal LCs, together with
CD83-positive, Langerin-negative DCs along the dermal–epidermal junction.
Bar¼200 mm.
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Figure 6. Immunohistochemistry with anti-keratin K6, anti-keratin K16, and
anti-C/EBPb antibody. (a) Keratin 6 staining of perilesional epidermis shows
suprabasal staining. (b) Keratin 16 staining of perilesional epidermis shows
suprabasal staining. (c) C/EBPb staining of perilesional skin shows strong
nuclear staining throughout the epidermis. (d) C/EBPb staining of distant area
skin of a psoriatic patient shows nuclear staining only in the granular layer.
(a–d) Bar¼ 200mm.
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skin, but less in number when compared with the perilesional
skin of psoriatic plaques. Several investigations have reported
the localization and number of LCs in psoriatic lesions.
Haftek et al. (1983) reported that OKT6-positive LC in
psoriatic lesions were reduced in number. Deguchi et al.
(2002) showed that the number of CD1a-positive epidermal
LCs in psoriatic lesions was not significantly different from
that of normal controls. CD1a expression in psoriatic skin
increased after treatment with propylthiouracil (Elias et al.,
2003), which suggested their decrease in the psoriatic lesion.
Oxholm et al. (1987) found that the number of LCs in the
uninvolved skin of psoriatic patients was significantly
decreased compared to that in healthy controls. A recent
study by Gilleaudeau et al. (2005) showed that CD1a-positive
LCs were increased in number in psoriatic lesions compared
to healthy controls and uninvolved skin of psoriatic patients,
and that there was no difference in numbers between the skin
of healthy controls and uninvolved skin of psoriatic patients.
Gordon et al. (2005) showed that lesional epidermis
contained a lower number or density of LCs, which was
restored by treatment with adalimumab, in which they
normalized the number of LCs with the epidermal thickness,
which makes the number of LCs in the lesional epidermis
much smaller than other investigations. The reason for these
conflicting results is not clear. One possible explanation
would be the different LC numbers in the different stages or
sites of psoriatic plaques. It is generally accepted that
psoriatic plaques develop eccentrically, thus the edge of the
plaques is developing as a psoriatic lesion.
Our results clearly demonstrated that the number of LCs
per unit length of skin in the perilesional epidermis was
significantly higher than that of uninvolved, or distant area
skin of psoriatic patients, and the proportion of the CD1a-
positive area was highest in the perilesional epidemis
compared to lesional epidemis or uninvolved epidermis of
psoriatic patients. The CD1a-positive area can reflect the
dendricity of LCs in the epidemis. Previous studies reported
that keratincoytes could be positive for CD1a in certain skin
disorders (Willemze et al., 1985; Lotti et al., 1992). However,
in our investigation, CD1a-positivity coincided with the
Langerin-positivity in double staining, which means that
CD1a-positiveness means the existence of LCs in the
epidermis. These observations imply highly dendritic LCs
increased in number in the epidermis during the very early
changes in plaque formation in psoriasis. LCs in perilesional
skin of psoriatic plaques coexpressed CD80, CD86, and
CD83, whereas LCs in the uninvolved epidermis distant from
the lesion did not. These LCs in the perilesional epidermis
were at the same time positive for Langerin. It is well
accepted that immature LCs with strong Langerin expression
show low levels of CD83, CD86, and HLA-DR and the
expression of these molecules is enhanced according to the
maturation of LCs, accompanying the loss of Langerin
expression (Berthier-Vergnes et al., 2005).The coexpression
of mature and immature markers on the LCs in the
perilesional epidemis of patients with psoriasis is demon-
strated for the first time in this study. Interestingly, Ohki et al.
(1997) demonstrated that the lesional epidermis of patients
with atopic dermatitis contains CD80- and CD86-positive
LCs, confirmed by the double staining with anti-CD1a
antibody, which is consistent with our observations.
In the perilesional skin, mild CD3-positive cell infiltration
was observed in the dermis, however, few CD3-positive cells
were detected in the epidermis. Interestingly, in the perile-
sional epidermis, CD3-positive T cells were hardly detect-
able. This was in sharp contrast to the lesional skin of
psoriatic plaques, where abundant CD3-positive cells were
observed both in the epidermis and in the dermis as
previously reported (Chamian et al., 2005). This was in
contrast to the increased number of LCs in the perilesional
epidermis. T lymphocytes are the target of many therapeutic
approaches to psoriasis and considered to be the main player
in the formation of psoriatic plaques. Our results, however,
suggest that LCs, which are more abundant and highly
dendritic in the perilesional epidermis, may be the main
participant in the early stages of the formation of plaques
compared to the sparse infiltrating T lymphocytes in the
perilesional skin.
In the perilesional and lesional skin of psoriatic plaques,
comparable numbers of CD11c-positive, CD11b-negative,
CD1a-negative, Langerin-negative, and CD83-positive DCs
were found in the dermis along the epidermal basement
membrane. These DCs are another possible participant in the
early psoriatic change, which we revealed to have a
prominent existence in the perilesional psoriatic epidermis.
These cells fulfill the criteria for dermal DCs (McLellan et al.,
1998). They are distinct from ‘‘epithelium-lining cells’’ of
psoriatic lesions, which are CD83-negative, CD11c-positive,
Langerin-negative, and CD14-positive macrophages, in terms
of surface markers and tissue distribution (Van den Oord and
de Wolf-Peeters, 1994). They also differ from inflammatory
dendritic epidermal cells in that they do not express CD1a or
CD11b (Wollenberg et al., 1999). Our observations revealed
many more CD83-positive cells than the report by Koga et al.
(2002). This is not surprising because they utilized formalin-
fixed paraffin-embedded samples, which they treated with
0.1% trypsin for 60 minutes. The antigenesity of CD83 may
not be fully retained with their procedure.
A subset of patients showed significant clinical improve-
ment in psoriasis after 12 weeks administration of alefacept,
the soluble lymphocyte function-associated antigen–3Ig
fusion protein (Ellis and Krueger, 2001) and that responding
patients showed marked reductions in disease-associated
T-cell subsets, expression of proinflammatory genes, and
CD11c-positive/CD83-positive DC subsets (Chamian et al.,
2005), which suggests the importance of these cells in the
progression of psoriasis. This is the first study to show so
many CD83-positive DCs in the perilesional normal-appear-
ing skin of psoriatic plaques. These two types of DCs are
abundantly distributed in the perilesional psoriatic lesions,
which support the hypothesis that these DCs have some roles
in the early event in the formation of psoriatic plaques.
BDCA2-positive DCs, presumably the plasmacytoid DCs,
were detectable only in the lesional skin of psoriatic plaques,
but not in the perilesional skin, in the uninvolved skin or in
the distant skin. Plasmacytoid DCs are reported to play a
www.jidonline.org 1919
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critical part in initiating the development of psoriatic lesions
(Nestle et al., 2005). In their report, there were many
plasmacytoid DCs in the lesional papillary dermis of patients
with psoriasis. In our study, however, only a few BDCA-
positive plasmacytoid DCs were found in the papillary dermis
and in the mid dermis of psoriatic lesions. The reason for this
discrepancy is not clear. Possible explanations include
differences in the genetic background of psoriatic patients
between Europeans and Japanese or the difference in the
detectable range of the BDCA2 antigen between their method
and ours.
In the perilesional slightly acanthotic skin, the epidermis
expressed K16 and to a lesser extent, K6 in the suprabasal
area and strong K16 and K6 expression was observed in the
lesional markedly acanthotic epidermis of psoriatic plaques.
In the epidermis of perilesional skin as well as lesional skin of
the psoriatic plaques, strong C/EBPb nuclear staining was
observed in the suprabasal area of the epidermis, whereas
C/EBPb nuclear staining was seen only in granular layers in
the normal appearing skin distant from the psoriatic plaques.
The epidermis of psoriatic plaques expresses many inflam-
matory molecules including ICAM1, HLA-DR, and inflam-
matory keratins such as keratin K6, K16, and K17 (Griffiths
et al., 1989; Komine et al., 1996). Those inflammatory
molecules have been thought to be induced by inflammatory
cytokines produced by infiltrating lymphocytes (Griffiths
et al., 1989; Komine et al., 1996). In the perilesional skin of
psoriatic plaques, which we regard to be the earliest form of
the psoriatic lesion, prominent K16 and K6 expression
together with C/EBPb nuclear staining was observed accom-
panied by acanthotic epidermal change. These inflammatory
changes support the idea that this area represents the initial
stages in the development of psoriatic plaques. There have
been several reports investigating the early changes of
psoriatic lesions based on the phenotypic changes in
surrounding normal-looking skin (perilesional skin). de Mare
et al. (1990) and Castelijns et al. (1999) reported that the
symptom-less skin adjacent to relapsing lesions showed a
marked expression of keratin K16 and epidermal growth
factor receptor. Van de Kerkhof et al. (1991) showed
increased skin-derived antileukoproteinase expression in the
marginal perilesional zone of the spreading psoriatic lesion.
The increased expression of C/EBPb in the perilesional area of
psoriatic plaques was demonstrated for the first time in this
report.
The cause of the activation of KCs in the perilesional skin
is unknown. We could hardly detect CD3-positive T cells in
the epidermis of the perilesional skin although focal CD3-
positive T cells were detected in the reticular dermis. This
suggests that early psoriatic changes in the perilesional skin of
psoriatic plaques accompanied activation of KCs without
T-cell involvement. Instead, we found highly dendritic CD83-
positive, Langerin-positive LCs in the perilesional epidermis.
Those LCs coexpressed CD80 and CD86, which indicates
that those LCs are maturing LCs. These observations suggest
that Langerin-positive, activated LCs stimulate neighboring
KCs, resulting in the nuclear expression of C/EBPb and
expression of keratin K6 and K16. Schweizer and Marks
(1977) suggested a role for LCs in influencing the degree of
keratinization as early as 1977.
Another interesting observation was that CD11c-positive,
CD11b-negative, CD1a-negative, Langerin-negative, CD83-
positive DCs, presumably dermal DCs, were observed in the
dermis along the epidermal basement membrane. These cells
may participate in early inflammatory changes in keraitno-
cytes during the formation of psoriatic plaques. No clear
evidence has emerged regarding the activation of KCs by
DCs. Recently, CD83-positive, CD11c-positive DCs in
psoriatic lesions have been reported to produce tumor
necrosis factor (TNF)-a and iNOS in situ, which are similar
to the TNF- and iNOS-producing DCs or ‘‘Tip-DC’’s in mice
(Lowes et al., 2005). TNF-a, produced by Tip-DCs, is a
proinflammatory cytokine, which can activate KCs, with the
expression of K6 through C/EBPb (Komine et al., 2000), and
numerous inflammatory cytokines, growth factors, and
adhesion molecules (Banno et al., 2004), including IL-1,
TNFa, and vascular endothelial growth factor. iNOS can
induce production of NO by DCs, KCs, and other types of
cells, which in turn stimulates divers types of cells to express
inflammatory cytokines. NO is reported to enhance IL-8
production from KCs stimulated by IL-1b (Andrew et al.,
1999), trigger vascular endothelial growth factor expression
in HaCaT keraitnocytes (Frank et al., 1999), and stimulate the
activity of IL-1 released from macophages (Hill et al., 1996),
all of which are important participants in psoriasis. Trans-
genic mice expressing vascular endothelial growth factor in
epidermis spontaneously develop psoriatic skin eruptions
(Xia et al., 2003), which makes it seem that these DCs directly
activate KCs, then trigger psoriatic changes to form mature
psoriatic plaques. Recent studies utilizing mice deficient in
JunB and c-Jun, demonstrated that T cells are dispensable in
inducing the psoriatic skin changes in these mice (Zenz et al.,
2005), which supports our hypothesis that DCs could induce
inflammatory epidermal changes before infiltration of
T lymphocytes in the very early stages in the formation of
psoriatic plaques.
MATERIALS AND METHODS
Immunohistochemistry
The clinical protocol of this study was approved by the institutional
ethical committee of Faculty of Medicine, University of Tokyo, and
was conducted in accordance with the guidelines set forth in the
Declaration of Helsinki Principles. All subjects signed informed
consent.
Skin biopsies were taken from peripheral lesions together with
the adjacent normal-appearing skin (considered as perilesional and
uninvolved) from 11 patients with typical plaque-type psoriasis after
obtaining informed consent. Skin biopsies from normal-appearing
skin, 2 cm or more distant from the plaques (distant area skin) were
also taken from three of the above psoriasis patients with their
informed consent (Figure 1). Systemic and topical treatment was
stopped 2 weeks before biopsy was done. These patients with their
psoriasis area severity index score and their clinical information are
listed in Table 1. The samples were embedded in OCT compound
without fixation and frozen. The frozen tissues were sectioned into
6-mm thick sections with a cryostat, fixed with cold acetone for
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5 minutes, incubated with primary antibodies overnight at 41C,
washed with phosphate-buffered saline, incubated with secondary
antibodies for 2 hours at room temperature, and stained with an
avidin–biotin method using diaminobenzidine (Wako, Tokyo, Japan)
as a substrate for peroxidase (Peroxydase ABC staining kit from Vector
Laboratories Inc., Burlingame, CA). They were mounted and covered
with cover glass slides and observed under a light microscope.
Double-immunofluorescent staining was performed utilizing
anti-goat IgG antibody conjugated with alexafluor 568 and anti-
mouse IgG antibody conjugated with alexafluor 488 (Molecular
Probes, Eugene, OR) as secondary antibodies. The tissues were
mounted with glycerol and observed under a fluorescence micro-
scope, Biozero from Keyence (Tokyo, Japan) with Nikon Plan Apo
original magnification  10, 20, and 40 lenses.
Antibodies
The primary antibodies used are as follows: anti-human keratin K6
antibody (Progen Biothchnik GMBH, Heidelberg, Germany), anti-
human keratin K14 antibody (Neo Markers, San Diego, CA), anti-
human keratin K16 antibody (YLEM, Rome, Italy), anti-human
C/EBPb antibody (Santa Cruz Biotechnology, Santa Cruz, CA), and
anti-human CD11b antibody (Abcam Ltd., Cambridge, UK). Anti-
human CD1a, CD3, CD4, CD8, CD11c, CD80, CD86, and CD83
antibodies were from BD Biosciences, San Diego, CA). Anti CD83
antibody conjugated with FITC (Invitrogen, San Diego, CA) was
utilized in the double immunofluorescence microscopy. Anti-
BDCA2 was from Miltenyi Biotec (Bergisch Gladbach, Germany).
Anti-Langerin antibody was from R&D systems, Minneapolis, MN).
Statistical analysis
Two sections of each sample were stained per one antibody, at least
two of each location (lesion, perilesion, uninvolved, and distant area
skin) were photographed per each section, and utilized for further
investigation.
The ratio of the positive area to the epidermis was evaluated
using the image analysis software Image Pro Plus version 4.5 from
Planetron (Tokyo, Japan). The ratio of positive area to the epidermis
of each lesion was compared to the other and a statistical analysis
was performed with the Mann–Whitney U-test. The level of
significance was Po0.05.
For the numbers of CD1a-positive cells, each low power field
(original magnification  10) was photographed and CD1a-positive
cells in the epidermis with cell body were counted independently by
two experienced dermatologist (MK and MK) and statistically
analyzed with the Wilcoxon signed rank test. The level of
significance was Po0.05. For the numbers of CD83-positive cells,
each high power field (original magnification  40) was photo-
graphed and CD83-positive cells interacting with the basal layer of
the epidermis were counted independently by two experienced
dermatologist (MK and MK) and statistically analyzed with the
Wilcoxon signed rank test. The level of significance was Po0.05.
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